National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.
about
Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?The relationship between Lp(a) and CVD outcomes: a systematic reviewLipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature reviewEgg Consumption and Human Cardio-Metabolic Health in People with and without DiabetesPharmacogenomics of statins: understanding susceptibility to adverse effectsPCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaRole of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee RecommendationsCardiovascular Complications of HIV Infection.Hypertriglyceridemia: the importance of identifying patients at risk.Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©.Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia.PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients.Cardiovascular Risk Stratification and Statin Eligibility Based on the Brazilian vs. North American Guidelines on Blood Cholesterol Management.The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk.Saturated Fatty Acids and Cardiovascular Disease: Replacements for Saturated Fat to Reduce Cardiovascular Risk.Hierarchical modelling of blood lipids' profile and 10-year (2002-2012) all cause mortality and incidence of cardiovascular disease: the ATTICA study.Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk.Association between serum non-high-density lipoprotein cholesterol and cognitive impairment in patients with acute ischemic strokeEffect of phytosterols and inulin-enriched soymilk on LDL-cholesterol in Thai subjects: a double-blinded randomized controlled trial.Prevalence of Nontraumatic Osteonecrosis of the Femoral Head and its Associated Risk Factors in the Chinese Population: Results from a Nationally Representative SurveyRecent Update to the US Cholesterol Treatment Guidelines: A Comparison With International Guidelines.Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids.Relationship between non-high-density lipoprotein cholesterol and carotid atherosclerosis in normotensive and euglycemic Chinese middle-aged and elderly adults.Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trialsRecent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.Genetics of Dyslipidemia and Ischemic Heart Disease.Alirocumab: A Review in Hypercholesterolemia.Approach to Statin Use in 2016: an Update.Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.Discontinuation of Statins: What Are the Risks?Statin combination therapy and cardiovascular risk reduction.Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.A systematic review to assess adherence and persistence with statins.Dyslipidemia in patients with chronic kidney disease.Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed-care population.Translating Guidelines Into Practice: Interpreting the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.
P2860
Q26740253-3FD2BAE5-037F-4C8C-A264-30B00F5F3867Q26749317-6EF096A2-FDFF-4C85-9AF0-6259DB400871Q26771862-B295142E-C68F-40E4-8521-6BC93E7E5246Q26781299-B0AE5D2E-AF6A-442A-AAF0-221BB6B1CF92Q28079822-BCAFE96D-4001-4507-B885-02A75CD510E9Q28275648-80DF24EC-2A5E-4186-AD67-42915645224AQ29994487-923A8E18-9A08-4500-AFA9-7D51D67829A9Q30235920-159DDDC9-0243-45B4-9BA7-F6DB0ADC3AFFQ30244825-BCB9D9A0-E8A0-4A7A-B30F-45795A54EDF5Q30248710-1467D5B8-904A-4E4E-95C2-54B518C162CEQ30848030-D22AF02B-5DD4-49D3-B3C2-197FCF086C21Q33590874-8EB9B013-E7B0-4EC0-B7D0-D7C92A24FC58Q33625574-0E4F3F8F-7A76-4B96-8216-2B5D4090C092Q33678940-32A0CC93-DC22-4EA6-BB0F-2794ACB4BDA1Q33848763-9BD4B4F7-D92B-498B-BADA-540451761281Q33848767-F80D92C0-E9E8-4864-988B-C834BB2CF596Q33856033-DBA09423-7226-4E26-BD82-8734CE92E5C6Q36061533-5CD0E172-65C3-4EC5-91E4-248D25C83463Q36103282-A1DDEB0B-18FD-45D7-B4CC-7FA9234D3ACFQ36113273-21683BC2-76D2-4AD0-9F7A-F5FD56EDB51DQ36267579-7C2CAB91-62F2-4BCE-8907-3C620203EAF1Q36589048-F7D50F55-1953-492C-94A5-2DCA8DC797FFQ36873040-5F42043D-D578-4E59-81D7-A5DA46B9ED25Q37034257-3AA0551D-F1CA-4EBC-9122-4B6466C23AAEQ37488469-689A8C8F-3060-41F6-9AC2-25B8B627763EQ37672465-D36B28E7-DB41-404B-99F9-880B69EBAA82Q37708496-5B35C509-AE01-4364-A8AE-040349A4E1BBQ37736674-A2DF3BE1-2CEF-4C40-A3AF-7C22C4207104Q38644870-0EE27E45-E12F-4F88-A09E-2FEE1C10A5CBQ38692446-36196625-4510-4C66-885D-83F56D7EC306Q38758372-7D46873E-AF34-41A1-AD3C-7B745355A8FCQ38773373-3080F7DE-5361-400E-97E9-A02E2A968579Q38828773-F5CB1FA7-44DB-459A-9318-EE73D8A7D101Q38843485-BCCFFCC3-3153-4BD5-B955-180C0D292054Q38881156-D4C961A0-FFB1-4C21-81F1-0D4460462FF4Q38882294-569BAF6E-457E-4176-B94F-D52BD063A62CQ39026831-20447C02-D2D1-4A23-9EFB-6540B4496867Q39045120-CED1914F-2A39-4A5E-B538-A02D7811724EQ39062795-E473265B-6213-41AC-B303-E782D3E744F0Q39382137-529EC4D4-304B-4039-8FFE-B2255E0FC447
P2860
National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
National lipid association rec ...... ipidemia: part 1--full report.
@en
National lipid association rec ...... ipidemia: part 1--full report.
@nl
type
label
National lipid association rec ...... ipidemia: part 1--full report.
@en
National lipid association rec ...... ipidemia: part 1--full report.
@nl
prefLabel
National lipid association rec ...... ipidemia: part 1--full report.
@en
National lipid association rec ...... ipidemia: part 1--full report.
@nl
P2093
P1476
National lipid association rec ...... ipidemia: part 1--full report.
@en
P2093
Carl E Orringer
Don P Wilson
Edward A Gill
Harold E Bays
James M McKenney
Kevin C Maki
Matthew K Ito
Peter H Jones
Robert A Wild
Scott M Grundy
P304
P356
10.1016/J.JACL.2015.02.003
P407
P577
2015-03-01T00:00:00Z